Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 15Terminated 7Unknown 3Recruiting 3Active not recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

NSCLC 1

Interventions

Carboplatin 79Cisplatin 74Bevacizumab 62Radiotherapy 59Drug Therapy 57Capecitabine 57Oxaliplatin 56tislelizumab 54toripalimab 45Paclitaxel 44Gemcitabine 43Specimen Handling 41pembrolizumab 40anlotinib 40sintilimab 37Cyclophosphamide 34130-nm albumin-bound paclitaxel 34Injections 29Pemetrexed 28camrelizumab 26Surgical Procedures, Operative 26Magnetic Resonance Spectroscopy 26lenvatinib 24apatinib 23Docetaxel 23Etoposide 22Biopsy 22S 1 (combination) 21Fluorouracil 21Immune Checkpoint Inhibitors 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × Diphenhydramine × Clear all
NCT07358689 2026-01-22

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
120 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡